Marieta Toma
Prof. Dr. Marieta Toma
  • Pathologie, Universitätsklinikum Bonn
Research topics
  • tumor models
  • organoid models
  • therapy resistance
In our lab we established a protocol for the cultivation of primary cell cultures, organoids and air-liquid-Interface organoids from several tissue types, including several cancer entities. Our main goal is to establish a routinely applicable model in order to integrate clinical and in vitro Information, in order to investigate molecular processes of tumor progress, therapy answer and therapy resistance mechanisms.
Selected publications

Simon AG, Esser LK, Ellinger J, Branchi V, Tolkach Y, Müller S, Ritter M, Kristiansen G, Muders MH, Mayr T, Toma MI (2020) J Cancer Res Clin Oncol. doi: 10.1007/s00432-020-03278-8 Borkowetz A, Froehner M, Rauner M, Conrad S, Erdmann K, Mayr T, Datta K, Hofbauer LC, Baretton GB, Wirth M, Fuessel S, Toma M*, Muders MH* (2019) Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate. Int J Cancer Sep 11. doi: 10.1002/ijc.3267

Peitzsch C, Cojoc M, Hein L, Kurth I, Mäbert K, Trautmann F, Klink B, Schröck E, Wirth MP, Krause M, Stakhovsky EA, Telegeev GD, Novotny V, Toma M, Muders M, Baretton GB, Frame FM, Maitland NJ, Baumann M, Dubrovska A (2016). An epigenetic reprogramming strategy to resensitize radioresistent prostate cancer cells. Cancer Res 76(9):2637-51.

Toma M, Wehner R, Kloß A, Hübner L, Fodelianaki G, Erdmann K, Fuessel S, Zastrow S, Meinhardt M, Seliger B, Brech D, Noessner E, Tonn T, Schaekel K, Bornhaeuser M, Bachmann MP, Wirth MP, Baretton G, Schmitz M (2015) Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis. Oncoimmunology; 4:e1008342.

Marieta Toma
Prof. Dr. Marieta Toma
Wird geladen